ESMO 2025 – Incyte impresses in KRAS G12D
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
And Treeline and HengRui also get in on the pan-RAS act.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.